Global Clinical Trail Manager for Isofol Medicals, Robert is pivotal in Phase III study for first line metastatic colorectal cancer. Isofol Medical is a small Biotech company committed to develop arfolitixorin for treatment of colorectal cancer. He has the overall oversight of the study as well as detailed management of individual countries in Europe. The study is in the recruitment phase, and the focus is to deliver study patients for the interim analysis scheduled for June 2020. During this period he is focusing on driving the study team, following-up with vendors and collaborating with local CRAs. Depending on the outcome of the interim analysis, the study population might be increased to achieve statistical power.
Check out the incredible speaker line-up to see who will be joining Robert.
*Processing your payment may take a moment. Please click submit payment only once, and do not refresh this page. Doing so may result in your credit card being charged more than once.